{
    "clinical_study": {
        "@rank": "52103", 
        "arm_group": {
            "arm_group_label": "Neuroblastoma", 
            "arm_group_type": "Experimental", 
            "description": "This is a single-arm, open label, open access study to provide the anti-GD2 murine IgG3 MoAb 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) to patients with high-risk neuroblastoma (NB). This immunotherapy has shown efficacy against minimal residual disease (MRD) in such patients."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to be able to supply an experimental combination of drugs\n      called 3F8 and GM-CSF (also called sargramostim) to patients with high-risk neuroblastoma\n      who may benefit from treatment."
        }, 
        "brief_title": "Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma", 
        "condition": "Neuroblastoma", 
        "condition_browse": {
            "mesh_term": "Neuroblastoma"
        }, 
        "detailed_description": {
            "textblock": "This treatment uses 3F8/GM-CSF and isotretinoin for: Group 1 patients are in 1st CR/VGPR;\n      Group 2 patients are in a \u22652nd CR/VGPR; and Group 3 patients have primary refractory NB in\n      BM. All patients will receive 3F8/GM-CSF through 24 months.\n\n      Road Map/Schema for Group 1 (1st CR/VGPR) and Group 2 (\u22652nd CR/VGPR) patients:\n\n      Cycle 1 3F8 (iv) + GM-CSF subcutaneous (sc) (1 wk) 2-4-wk interval Cycle 2 3F8 (iv) + GM-CSF\n      (sc) (1 wk) 2-4-wk interval* - oral isotretinoin x14 days Cycle 3 3F8 (iv) + GM-CSF (sc) (1\n      wk) 2-4-wk interval - oral isotretinoin x14 days Cycle 4 3F8 (iv) + GM-CSF (sc) (1 wk)\n      6-8-wk interval - oral isotretinoin x14 days on, 14 days off, 14 days on Cycle 5 3F8 (iv) +\n      GM-CSF (sc) (1 wk) 6-8-wk interval - oral isotretinoin x14 days on, 14 days off, 14 days on\n      (6th cycle) Cycle 6 3F8 (iv) + GM-CSF (sc) (1 wk) 6-8-wk interval Cycle 7 3F8 (iv) + GM-CSF\n      (sc) (1 wk) Continue with 6-8-wk intervals through 24 months from 1st dose of 3F8. *\n      assessment of BM status by standard histology\n\n      Road Map/Schema for Group 3 patients (BM positive): The break between end of a cycle of\n      3F8/GM-CSF and start of next cycle is approximately 2-to-4-weeks through 4 cycles after\n      achievement of CR in BM; subsequent breaks are ~6-8 weeks. Please see roadmap below for a\n      patient achieving CR in BM after cycle 1. Cycle 1 3F8 (iv) + GM-CSF (sc) (1 wk) 2-4-wk\n      interval* - BM negative Cycle 2 3F8 (iv) + GM-CSF (sc) (1 wk) 2-4-wk interval* - oral\n      isotretinoin x14 days Cycle 3 3F8 (iv) + GM-CSF (sc) (1 wk) 2-4-wk interval - oral\n      isotretinoin x14 days Cycle 4 3F8 (iv) + GM-CSF (sc) (1 wk) 2-4-wk interval - oral\n      isotretinoin x14 days Cycle 5 3F8 (iv) + GM-CSF (sc) (1 wk) 6-8-wk interval - oral\n      isotretinoin x14 days Cycle 6 3F8 (iv) + GM-CSF (sc) (1 wk) 6-8-wk interval - oral\n      isotretinoin x14 days on, 14 days off, 14 days on (6th cycle) Cycle 7 3F8 (iv) + GM-CSF (sc)\n      (1 wk) 6-8-wk interval Continue with 6-8-wk intervals through 24 months from 1st dose of\n      3F8.\n\n      * assessment of BM response by standard histology"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of NB as defined by international criteria,62 i.e., histopathology\n             (confirmed by the MSKCC Department of Pathology) or BM metastases plus high urine\n             catecholamine levels.\n\n          -  High-risk NB, as defined by risk-related treatment guidelines and the International\n             NB Staging System, i.e., stage 4 with (any age) or without (>18 months)\n             MYCNamplification, 63 or MYCN-amplified NB other than stage 1.64,65\n\n          -  Patients are in CR/VGPR or have primary refractory NB in BM - i.e., NB resistant to\n             standard therapy, as evidenced by persistence of NB in BM by histology or MIBG scan,\n             but all other findings in scans show VGPR.\n\n          -  Children and adults are eligible.\n\n          -  Signed informed consent indicating awareness of the scheduling and side effects, as\n             well as testing requirements, of this program.\n\n        Exclusion Criteria:\n\n          -  Existing severe major organ dysfunction, i.e., renal, cardiac, hepatic, neurologic,\n             pulmonary, or gastrointestinal toxicity > or = to grade 3, except for grade 3\n             hematologic toxicity.\n\n          -  Progressive disease (PD)\n\n          -  History of allergy to mouse proteins.\n\n          -  Active life-threatening infection.\n\n          -  Human anti-mouse antibody (HAMA) titer >1000 Elisa units/ml.\n\n          -  Pregnant women\n\n          -  Inability to comply with protocol requirements."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "125", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02100930", 
            "org_study_id": "13-260"
        }, 
        "intervention": [
            {
                "arm_group_label": "Neuroblastoma", 
                "intervention_name": "Anti-GD2 3F8 Monoclonal Antibody", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Neuroblastoma", 
                "intervention_name": "GM-CSF (granulocyte-macrophage colony-stimulating factor)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Neuroblastoma", 
                "intervention_name": "oral isotretinoin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Immunoglobulins", 
                "Antibodies, Monoclonal", 
                "Isotretinoin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Anti-GD2 3F8 Monoclonal Antibody", 
            "oral isotretinoin", 
            "GM-CSF", 
            "Sargramostim", 
            "13-260"
        ], 
        "lastchanged_date": "March 27, 2014", 
        "link": {
            "description": "Memorial Sloan Kettering Cancer Center", 
            "url": "http://www.mskcc.org/"
        }, 
        "location": {
            "contact": {
                "last_name": "Brian Kushner, MD", 
                "phone": "212-639-6793"
            }, 
            "contact_backup": {
                "last_name": "Nai-Kong Cheung, MD, PhD", 
                "phone": "646-888-2313"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10065"
                }, 
                "name": "Memorial Sloan Kettering Cancer Center"
            }, 
            "investigator": {
                "last_name": "Brian Kushner, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma", 
        "overall_contact": {
            "last_name": "Brian Kushner, MD", 
            "phone": "212-639-6793"
        }, 
        "overall_contact_backup": {
            "last_name": "Nai-Kong Cheung, MD, PhD", 
            "phone": "646-888-2313"
        }, 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Brian Kushner, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "for patients treated in CR/VGPR -Disease status is defined by the International Neuroblastoma Response Criteria,supplemented by results of MIBG (metaiodobenzylguanidine) scans", 
                "measure": "relapse-free survival", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "of BM disease for patients with primary refractory NB- Disease status is defined by the International Neuroblastoma Response Criteria,supplemented by results of MIBG  (metaiodobenzylguanidine) scans", 
                "measure": "complete remission", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02100930"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}